Quintrio
Home

SERVICES-BUSINESS SERVICES, NEC

HealthEquity, Inc

HQY

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

Last trade $102.36
Day change -$2.22 (-2.12%)
Day range $99.82 – $106.50
Volume 212,714
Market cap $8.65B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$8.65B
Price / earnings
36.58×
Price / book
4.35×
Price / sales
6.35×
EV / sales
6.85×
EV / EBITDA
18.16×

Profitability

Earnings per share
$2.86
Return on assets
7.23%
Return on equity
11.88%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.47×
Current ratio
2.99×
Quick ratio
2.99×
Cash ratio
1.66×

Cash flow

Price / cash flow
17.65×
Price / free cash flow
18.5×
Free cash flow
$467.67M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for HQY, quarterly periods
Line itemQ2 FY2027 Jul 31, 2026Q1 FY2027 Apr 30, 2026Q4 FY2026 Jan 31, 2026Q3 FY2026 Oct 31, 2025Q2 FY2026 Jul 31, 2025Q1 FY2026 Apr 30, 2025Q4 FY2025 Jan 31, 2025Q3 FY2025 Oct 31, 2024
Revenue$350.73M$354.64M$334.59M$322.16M$325.84M$330.84M$311.82M$300.43M
Cost of revenue$92.78M$98.33M$106.44M$94.1M$93.24M$106.53M$122.77M$103.41M
Gross profit$257.95M$256.31M$228.15M$228.06M$232.6M$224.31M$189.04M$197.03M
Selling, general and administrative$58.08M$57.96M$58.45M$55.29M$49.91M$51.52M$53.06M$54.43M
Research and development$73.92M$67.77M$70.35M$65.92M$64.8M$61.44M$64.65M$60.19M
Total operating expenses$159.26M$153.36M$157.08M$149.37M$142.98M$141.23M$146.89M$177.4M
Operating income$98.69M$102.95M$71.07M$78.7M$89.61M$83.08M$42.15M$19.63M
Interest expense-$12.61M-$12.59M-$13.27M-$14.05M-$14.96M-$14.86M-$15.26M-$18.16M
Income before taxes$87.87M$92.41M$60.9M$67.53M$78.05M$70.95M$29.96M$6.22M
Income taxes$22.22M$23M$11.16M$15.84M$18.19M$17.04M$3.6M$515K
Net income$65.64M$69.42M$49.74M$51.69M$59.85M$53.92M$26.37M$5.7M
Net income attributable to common shareholders$65.64M$69.42M$49.74M$51.69M$59.85M$53.92M$26.37M$5.7M
EBITDA$141.62M$142.28M$111.08M$118.63M$129.33M$123.09M$83.51M$94.78M
Basic earnings per share$0.79$0.82$0.58$0.60$0.69$0.62$0.30$0.07
Diluted earnings per share$0.78$0.82$0.57$0.59$0.68$0.61$0.29$0.06

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Aytu BioPharma, Inc. (AYTU) Reports Q1 Loss, Beats Revenue Estimates

Aytu BioPharma reported a quarterly loss of $0.2 per share, missing consensus estimates of $0.1 loss, representing a -100% earnings surprise. The company posted revenues of $14.84 million, slightly beating estimates. With unfavorable estimate revisions, the stock received a Zacks Rank #5 (Strong Sell) rating and has declined 31.5% year-to-date versus the S&P 500's 10.5% gain.

Zacks Investment Research

Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates

Prime Medicine (PRME) reported a quarterly loss of $0.22 per share, beating consensus estimates of $0.23 loss by 4.35%, but missed revenue expectations with $4.21 million versus the consensus estimate, down 25.8%. The stock has outperformed the S&P 500 by 12.6% year-to-date but carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Zacks Investment Research

CryoPort, Inc. (CYRX) Reports Q3 Loss, Tops Revenue Estimates

CryoPort (CYRX) reported a quarterly loss of $0.25 per share, missing the consensus estimate of $0.19 loss by 31.58%. However, the company exceeded revenue expectations with $50.22 million versus the estimate of $48.68 million. The stock has gained 74% year-to-date but received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

Zacks Investment Research

BLCO vs. HQY: Which Stock Is the Better Value Option?

A comparison of two Medical Services stocks shows that Bausch + Lomb (BLCO) is more attractive for value investors than HealthEquity (HQY). BLCO has a stronger Zacks Rank of #1 (Strong Buy) versus HQY's #2 (Buy), and superior valuation metrics including a lower forward P/E ratio (21.20 vs 21.96), a significantly better PEG ratio (0.53 vs 1.36), and a lower P/B ratio (1.1 vs 4.31), earning it a Value grade of B compared to HQY's C grade.

Zacks Investment Research

Is HealthEquity (HQY) a Solid Growth Stock? 3 Reasons to Think "Yes"

HealthEquity (HQY) is highlighted as a compelling growth stock investment opportunity, featuring a Growth Score of B and Zacks Rank #2. The company demonstrates strong fundamentals including 18% projected EPS growth (above the 14% industry average), robust year-over-year cash flow growth of 22%, and positive earnings estimate revisions, positioning it as a potential outperformer for growth investors.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.